Zhejiang Better Pharmaceuticals Co., Ltd
Creation time：2004
Product category：
Position：Salessupervisor
Website：http://www.betterpharma.com/cn/
Exporting countries and regions：India, Pakistan, Japan and South Korea and other East And Southeast Asian countries, South America, Europe and The United States and other markets
Name of exhibits：ClarithromycinCAS: 81103-11-9
Minimum order quantity：10KG，25KG
Order delivery time：negotiable
Authentication：GMP/WC/FDA/CEP/
Buyer type：Pharmaceutical agents, pharmaceutical manufacturers
Zhejiang Better Pharmaceuticals Co., Ltd, located in the city of Shaoxing, Paojiang Industrial Zone, was originated in 2005. It is a joint-venture between Hong Kong Youchuang International Investment Group Co., Ltd, and Shaoxing Sunflower Investment Co., Ltd. with a registration capital amounts to $39,800,000. The total area encompasses approximately 153 acres. Better Pharma manufactures and sells APIs, pharmaceutical preparations, and pharmaceutical intermediates. The annual production capability can reach 500 tons of APIs; 1100,000,000 tablets as well as capsules; 40,000,000 units of lyophilized powder for injection.
The mission of Better Pharma is to strive for the highest level of performance to maximize its rapid development and become a leader in its product market. Based on the GMP standards, Better Pharma guarantees its customers only the highest quality, first class plants and equipment, first class technologies and manufacturing processes, and assurance of first class quality for all of its products.
Better Pharma commits itself to the advanced environment protection management level. Due to the awareness of the characteristics of high-energy consumption, high waste drainage and high pollution of medical industry, Better Pharma places special emphasis on the "recycling economic" development with the advanced environmental equipments and instruments. It is Better Pharma's firm commitment to society to create a "green enterprise" to bear the responsibilities for healthy environment for society.
Better Pharma enjoys close relationships in cooperation with many domestic and oversea R&D institutions. Many new drugs and research projects have been industrialized already and will become the dominant products of this company. There are currently dozens of new products undergoing the research and development procedures. The main R&D fields are focused on cardiovascular agents, antivirals for hepatitis B, anti-ulcer drugs, anti-infection drugs and immunosuppressants.
Providing better healthcare and protecting our environment are the goal and
